Low levels of human serum glucosamine after ingestion of glucosamine sulphate relative to capability for peripheral effectiveness

Annals of the Rheumatic Diseases

Volumn 65, Issue 2, 2006, Pages 222-226

  Biggee, B A ^b   Blinn, C M ^a   McAlindon, T E ^b   Nuite, M ^b   Silbert, J E ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHONDROITIN SULFATE; GALACTOSAMINE; GLUCOSAMINE; GLUCOSAMINE SULFATE;

ADULT; AGED; ARTICLE; CARTILAGE CELL; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; MALE; OSTEOARTHRITIS; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADULT; AGED; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLUCOSAMINE; HUMANS; MALE; MIDDLE AGED; OSTEOARTHRITIS; SENSITIVITY AND SPECIFICITY; TIME FACTORS;

EID: 31144471084     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2005.036368     Document Type: Article

References (29)

1. Mili F, Helmick CG, Zack MM. Prevalence of arthritis: analysis of data from the US Behavioral Risk Factor Surveillance System, 1996-99. J Rheumatol 2002;29:1981-8.
2. Pavelka K, Gatterova J, Olejarova M, Machacek S, Giacovelli G, Rovati L. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med 2002;162:2113-23.
3. Reginster JY, Deroisy R, Rovati LC, Lee RL, Lejeune E, Bruyere O, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001;357:251-6.
4. McAlindon TE, LaValley MP, Gulin JP, Felson DT. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA 2000;283:1469-75.
5. Richy F, Bruyere O, Ethgen O, Cucherat M, Henrotin Y, Reginster JY. Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis. Arch Intern Med 2003;163:1514-22.
6. Rindone JP, Hiller D, Collacott E, Nordhaugen N, Arriola G. Randomized, controlled trial of glucosamine for treating osteoarthritis of the knee. West J Med 2000;172:91-4.
7. Hughes R, Carr A. A randomized, double-blind, placebo-controlled trial of glucosamine sulphate as an analgesic in osteoarthritis of the knee. Rheumatology (Oxford) 2002;41:279-84.
8. Setnikar I, Pacini MA, Revel L. Antiarthritic effects of glucosamine sulfate studied in animal models. Arzneimittelforschung 1991;41:542-5.
9. Bassleer C, Rovati L, Franchimont P. Stimulation of proteoglycan production by glucosamine sulfate in chondrocytes isolated from human osteoarthritic articular cartilage in vitro. Osteoarthritis Cartilage 1998;6:427-3.
10. Mroz PJ, Silbert JE. Effects of [3H]glucosamine concentration on [3H]chondroitin sulphate formation by cultured chondrocytes. Biochem J 2003;376:511-15.
11. 35S]sulfate. Arthritis Rheum 2004;50:3574-9.
12. Setnikar I, Giacchetti G, Zanolo G. Pharmacokinetics of glucosamine in the dog and man. Arzneimittelforschung 1986;36:729-35.
13. 3H]glucosamine by endogenous hexosamine from glucose and other sources. Arch Biochem Biophys 1989;268:393-7.
14. Setnikar I, Palumbo R, Canali S, Zanolo G. Pharmacokinetics of glucosamine in man. Arzneimittelforschung 1993;43:1109-13.
15. Adebowale A, Du J, Liang Z, Leslie JL, Eddington ND. The bioavailability and pharmacokinetics of glucosamine hydrochloride and low molecular weight chondroitin sulfate after single and multiple doses to beagle dogs. Biopharm Drug Dispos 2002;23:217-25.
16. Aghazadeh-Habashi A, Sattari S, Pasutto F, Jamali F. Single dose pharmacokinetics and bioavailability of glucosamine in the rat. J Pharm Pnarm Sci 2002;5:181-4.
17. Noyszewski EA, Wroblewski K, Dodge GR, Kudchodkar S, Beers J, Sarma AVS, et al. Preferential incorporation of glucosamine into the galactosamine moieties of chondroitin sulfate in articular cartilage explants. Arthritis Rheum 2001;44:1089-95.
18. Lippiello L. Glucosamine and chondroitin sulfate: biological response modifiers of chondrocytes under simulated conditions of joint stress. Osteoarthritis Cartilage 2003;11:335-42.
19. Dodge GR, Jimenez SA. Glucosamine sulfate modulates the levels of aggrecan and matrix metalloproteinase-3 synthesized by cultured human osteoarthritis articular chondrocytes. Osteoarthritis Cartilage 2003;11:424-32.
20. Sandy JD, Gamett D, Thompson V, Verscharen C. Chondrocyte-mediated catabolism of aggrecan: aggrecanase-dependent cleavage induced by interleukin-1 or retinoic acid can be inhibited by glucosamine. Biochem J 1998;335:59-66.
21. Ilic MZ, Martinac B, Handley CJ. Effects of long-term exposure to glucosamine and mannosamine on aggrecan degradation in articular cartilage. Osteoarthritis Cartilage 2003;11:613-22.
22. Fenton JI, Chlebek-Brown KA, Peters TL, Caron JP, Orth MW. Glucosamine HCl reduces equine articular cartilage degradation in explant culture. Osteoarthritis Cartilage 2000;8:258-65.
23. Piperno M, Reboul P, Hellio Le Graverand MP, Peschard MJ, Annefeld M, et al. Glucosamine sulfate modulates dysregulated activities of human osteoarthritic chondrocytes in vitro. Osteoarthritis Cartilage 2000;8:207-12.
24. Gouze J-N, Bordji K, Gulberti S, Terlain B, Netter P, Magdalou J, et al. Interleukin-1 [beta] down-regulates the expression of glucuronosyltransferase I, a key enzyme priming glycosaminoglycan biosynthesis: influence of glucosamine on interleukin-1 [beta]-mediated effects in rat chondrocytes. Arthritis Rheum 2001;44:351-60.
25. Gouze JN, Bianchi A, Becuwe P, Dauca M, Netter P, Magdalou J, et al. Glucosamine modulates IL-1-induced activation of rat chondrocytes at a receptor level, and by inhibiting the NF-κB pathway. FEBS Lett 2002;510:166-70.
26. Largo R, Alvarez-Soria MA, Diez-Ortego I, Calvo E, Sanchez-Pernaute O, Egido J, et al. Glucosamine inhibits IL-1β-induced NFκB activation in human osteoarthritic chondrocytes. Osteoarthritis Cartilage 2003;11:290-8.
27. 2 in articular cartilage explants. Osteoarthritis Cartilage 2005;13:387-94.
28. Hua J, Sakamoto K, Nagaoka I. Inhibitory actions of glucosamine, a therapeutic agent for osteoarthritis, on the functions of neutrophils. J Leucocyte Biol 2002;71:632-40.
29. Ma L, Rudert WA, Harnaha J, Wright M, Machen J, Lakomy R, et al. Immunosuppressive effects of glucosamine. J Biol Chem 2002;277:39343-9.